BofA raised the firm’s price target on Sarepta (SRPT) to $18 from $16 and keeps an Underperform rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Mizuho biotech analysts hold an analyst/industry conference call
- Cautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus Findings
- NY panel recommends Medicaid pause coverage of DMD drug, STAT reports
- KalVista appoints Bilal Arif as COO, Linea Aspesi as CPO
- Iron Mountain, Lennar, Sarepta, Paycom, Guardant: Trending by Analysts